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The effect of flumazenil, a benzodiazepine antagonist, on hepatic encephalopathy was 
studied in rabbits with acute hepatic failure induced by a two-stage liver devascularization 
procedure. The rabbits were randomized for treatment with 5 mg/kg of flumazenil or the 
placebo. The drug was administered attwo easily recognizable time points in the course of 
the encephalopathy: first, when the righting reflex was disturbed, and second, when the 
animal could no longer achieve to the sitting position. The response after flumazenil did not 
differ from that after the placebo, as measured by clinical evaluation and automated EEG 
analysis. Furthermore, the progression of the encephalopathy, as measured by the survival 
time after the first injection, was not affected by flumazenil. 
KEY WORDS: flumazenil; hepatic encephalopathy; acute hepatic failure; rabbits; experi- 
mental. 
INTRODUCTION 
Benzodiazepine r ceptor antagonists have been reported to improve hepatic encephalo- 
pathy (HE) in experimental  (Baraldi  et al., 1984; Bassett et al., 1987; Gammal  et al., 
1988; Zenerol i  et al., 1988) as well as clinical (Scol lo-Lavizzari  et al., 1985; Bansky 
et al., 1985, 1989; Ferenci et al., 1989; Burke, 1988; Gr imm et al., 1988) studies. The 
benzodiazepine receptor is part  of  the larger 7-aminobutyr ic acid (GABA) -  
benzodiazepine r ceptor complex (Braestrup et al., 1983). It has been suggested that 
this receptor system may play a role in the pathogenesis of  HE  (Jones et al., 1984). 
Gamma-aminobutyr i c  acid is the most important  inhibitory neurotransmitter,  
accounting for 30-40% of the total neurotransmitter  content in the brain (Walker, 
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1983). The binding of GABA to its receptor, and thus its inhibitory action on 
neuronal membranes, i  enhanced by the binding of benzodiazepines to their own 
receptors (Braestrup et aI., 1983). Benzodiazepine antagonists inhibit the binding of 
benzodiazepines but, on their own, are not believed to have an important intrinsic 
effect on central nervous ystem functioning (Braestrup et al., 1983). Therefore, apart 
from offering a new therapeutic approach to HE, benzodiazepine antagonists may be 
important in studies on its pathogenesis: a beneficial effect may point to the presence 
of endogenous benzodiazepine-like compounds inHE, as has been recently suggested 
(Basile et al., 1988). 
Various compounds that antagonize the benzodiazepine r ceptor, have been 
studied in animal models of acute hepatic failure: flumazenil, CGS 8216, and Ro 15- 
4513. All ameliorated hepatic encephalopathy in rats and rabbits with galact0samine 
or thioacetamide-induced fulminant hepatic failure (Baraldi et al., 1984; Bassett et al., 
1987; Gammal et al., 1988; Zeneroli et al., 1988). However, abeneficial effect of CGS 
8216 could not be confirmed in rats with acute ischemic liver failure (Zieve et al., 
1987). Furthermore, antagonism of the GABA receptor itself also did not affect he 
course of hepatic encephalopathy in this animal model (Rzepczynski et al., 1986). 
Therefore, further experimental controlled studies on the effect of a benzodiazepine 
antagonist in hepatic encephalopathy are needed. We studied the effect of flumazenil 
in our recently described rabbit model of acute ischemic liver failure (Fick et al., 1987). 
We measured the response by clinical evaluation of HE, spectral analysis of the EEG, 
and determination f the survival time. 
MATERIALS AND METHODS 
Animals. Sixteen New Zealand white rabbits with acute ischemic liver failure 
were used. Four healthy control rabbits were studied to assess the intrinsic effect of 
flumazenil n comparison to that of diazepam. 
Rabbits with Acute Hepatic Encephalopathy. Before surgery the rabbits received 
doxycycline, indosages increasing to a maximum of 25 mg, in their drinking water for 
about 5 days. Food was withdrawn 24 hr before surgery, except for glucose drinking 
water ad libitum. Anesthesia was induced with Hypnorm (0.6-0.8mlim; 10mg of 
fluanison and 0.2mg of fentanyl base/ml). After intubation muscle relaxation was 
achieved with 1.0mg of Pavulon iv, and anesthesia was maintained with N20:O 2 
(2:1) and 0.025rag of fentanyl iv, whenever indicated. A Ringer-lactate solution 
(20 ml/hr) and Haemacel (10 ml/hr) were administered via a cannula in a marginal ear 
vein during the operation. To prevent acidosis, the infusion regimen was changed to 
8.4% sodium bicarbonate ata rate of 15 and 30 ml/hr during and immediately after 
construction of the portacaval shunt (PCS), respectively. To monitor arterial blood 
pressure, blood gases, and pH, a 5-Ch catheter was inserted in the right femoral 
artery. Fifty milligrams of amoxicilline was given as antibiotic prophylaxis. 
The surgical procedure was performed as previously described (Fick et al., 1987). 
After severing the attachments of the liver, a small-diameter (5-mm) side-to-side PCS 
was constructed with 7-0 prolene within 15 min. A loose ligature was placed around 
the hepatoduodenal ligament and threaded through a subcutaneous plastic tube. 
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Three silver electrodes were placed directly on the dura mater through small burr 
holes in the skull. Two were implanted 5mm to the right of the sagittal suture, 3 mm 
anterior and 11 mm posterior to the coronal suture, respectively, and the third was 
implanted 5mm to the left of the sagittal suture and 3 mm anterior to the coronal suture. 
Postoperatively the rabbits were given glucose water ad libitum, followed by 
a normal diet. The second day after surgery 50mg of amoxicilline was given iv 
and acute liver ischemia was induced by tightening the loose ligature around the 
hepatoduodenal ligament. To prevent hypoglycemia, n infusion of 10% glucose 
(5 ml/hr) was started, the dose being adjusted to maintain ormoglycemia, which was 
controlled hourly. Body temperature was measured every 2 hr and remained normal 
throughout the experiment. Before induction of liver ischemia nd at regular intervals 
in the course of the experiment, spectral analysis was performed and arterial blood 
samples were taken. Every half-hour the rabbits were taken out of their restraining 
boxes for evaluation of the stage of HE. Two easily recognizable clinical stages of HE 
could be identified in most animals. Stage A was characterized by a disturbed righting 
reflex: the animal not getting up immediately when placed on its side. At stage B the 
rabbit lay in the cage and could not come to the sitting position, not even after 
stimulation, and usually did not even lift its head. In some cases tage B was preceded 
by a period of agitation or marked ataxia. When stage A or B was identified the 
evaluation was repeated 10rain later for confirmation. 
The rabbits were randomized for treatment with flumazenil or placebo. Flumazenil 
or the vehicle, 5 mg/kg, was injected at a rate of 1 mg/kg/min. The effect of flumazenil 
on HE was evaluated clinically before and 10min after the injection as well as by 
spectral analysis before and 5 min after the injection and by determination of the 
survival time after the first injection of flumazenil or placebo. Liver failure was 
confirmed by a rise in arterial ammonia levels and a decline in clotting factors. 
Autopsy studies of all rabbits were performed to verify that the hepatoduodenal 
ligament was adequately clamped. 
Control Rabbits. Hypnorm, 0.5 ml/kg, was administered intramuscularly and 
electrodes were placed on the dura mater, as described above. The effect of flumazenil 
was assessed in a randomized crossover study performed at least 1 week after the 
surgical procedure. For this purpose 5 mg/kg of flumazenil or the vehicle was injected 
at a rate of 1 mg/kg/min. After a washout period of 1 week the other compound was 
given. The effect was assessed by clinical evaluation of the animal before and 10 min 
after the injection and by spectral analysis before and 5 min after the injection. A 
similar crossover study was carried out to evaluate the effect of 5 mg/kg of diazepam 
versus that of 0.9% saline. 
Spectral Analysis. The variations in potential between the electrodes over 
the right hemisphere were registered by an EEG apparatus (Ahrend-van Gogh, 
Amsterdam, The Netherlands) and fed into a computer at a sampling rate of 51.2 Hz 
and a sensitivity of 11 bits/5 V. A power spectrum was established, as described earlier 
(Van der Rijt et al., 1984). The frequency resolution was 0.1 Hz. The mean dominant 
frequency (MDF), the power, and the percentages of the delta, theta, alpha, and betha 
frequency bands were calculated over the frequency range 1.0-25.6 Hz. 
Chemicals. Flumazenil was kindly provided by Hoffmann-La Roche & Co, 
Mijdrecht, The Netherlands. Just before the experiment i  was suspended in sterile 
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distilled water at 37~ with Tween 80 (1 drop per 5 ml). Diazepam was solubilized in 
water with alcohol (10%) and propylene glycol (40%). Clotting factors were assessed 
by means of the Normotest (Nyegaard, Oslo, Norway). Arterial ammonia levels were 
measured by an enzymatic method using gluamate dehydrogenase. 
Statistics. The Wilcoxon two-sample t st was used for statistical comparisons. 
The effects on the MDF and survival times were analyzed with the paired or non- 
paired Student t test, whenever indicated; for analyzing the survival times logarithmic 
transformation was used. 
RESULTS 
Rabbits with Hepatic Encephalopathy. The degree of liver failure, as measured 
by the rise in arterial ammonia levels and the decline in Normotest values, in the group 
of rabbits treated with flumazenil was similar to that found for the placebo group 
(Fig. 1). 
At stage A the effect of flumazenil or placebo could be Studied in all 16 rabbits, 
although the time between the induction of liver ischemia nd the diagnosis of this 
stage of HE varied considerably: 1.5-11.0 hr for the flumazenil-treated and 1.5-10.5 hr 
for the placebo group. The righting reflex did not normalize in any of the rabbits after 
administration f either flumazenil or the placebo (Table I). Two rabbits treated with 
flumazenil and three rabbits receiving the placebo died before stage B was identified 
or confirmed (most of them were agitated just before death). Therefore, at stage B 
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Fig. l. Parameters of acute hepatic failure: on the left, the rise in arterial 
ammonia levels during the first 8 hr after induction of liver ischemia; on the 
right, the hourly decrease in clotting factors, as assessed by Normotest. The 
results are expressed as mean + SE. 
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Fig. 2. Survival times after the first injection of flumazenil or the placebo: 
on the left, absolute values; on the right the same survival times after 
logarithmic transformation to obtain a normal distribution ( , mean). 
Table I. Clinical Recovery After Flumazenil or Placebo 
Flumazenil Placebo 
Stage A 0/8 0/8 
Stage B 1/6 1/5 
six rabbits could be given flumazenil and five rabbits the placebo. In each group one 
animal died within 10 min of the injection and one animal regained the ability to sit 
(Table I). 
The survival times after the first injection of either flumazenil or the placebo are 
shown in Fig. 2. Logarithmic transformation of the data was used to obtain a normal 
distribution. As the mean ratio of the survival times for the two groups after adminis- 
tration of the first injection was 1.04 (with a 95% confidence interval of 0.72 to 1.49), 
progression of HE was similar for flumazenil and the placebo. 
The effects of flumazenil and placebo on the MDFs are shown in Table II and 
Fig. 3. At stage A the MDFs were already significantly decreased with respect o 
baseline values (paired Student's t test). At this stage neither flumazenil nor the 
placebo induced normalization to the baseline values (Table II). At stage B the MDFs 
were decreased further, except in one animal with an MDF higher than the baseline 
value; in this animal a further increase occurred from 5.9 to 8.1 Hz after flumazenil, 
due to a peak in the power spectrum around 15 Hz. A similar effect did not occur in 
other animals. At both stages of HE the changes in MDF with respect o the values 
before injection were calculated for each rabbit. The changes did not differ between 
flumazenil and placebo. At stage A the mean difference between flumazenil and 
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Table II. Changes in MDF (Hz) After Treatment of Hepatic Encephaiopathy 
Flumazenil or Placebo ~' 
Stage A Stage B 
Baseline Before After Before After 
137 
with 
Flumazenil 5.33 _+ 0.40 4.69 _+ 0.22* 4.55 __%_ 0.90** 4.20 _+ 1.20 4.28 _+ 2.27 
(8) (8) (8) (6) (5) 
Placebo 6.00 + 1.14 5.38 • 0.77*** 4.93 _+ 1.06" 4.92 • 1.41"* 3.60 _+ 0.74*** 
(8) (8) (8) (5) (4) 
"Results are expressed as means • SD, the number of rabbits is given in parentheses. 
*Difference with respect o baseline, P < 0.01. 
**Difference with respect o baseline, P < 0.02. 
***Difference with respect o baseline, P < 0.05. 
p lacebo was 0 .31Hz  with a 95% conf idence interval  o f  -0 .54  to 1.16Hz.  A t  
stage B the mean difference was 1.07 Hz,  with a 95% conf idence interval  o f  -0 .68  
to 2.82 Hz.  There  were also no differences in the effects on power  and the delta, 
theta, a lpha,  and beta percentages o f  the power  spectrum after the first as well as 
the second inject ion.  
Control Rabbits. The effects o f  f lumazeni l  and the p lacebo were studied in 
four  rabbits,  and the effects o f  d iazepam and phys io logic  saline in three rabbits.  
A f ter  f lumazeni l  behav iora l  changes did not  occur  and spectral  analysis showed 
only min ima l  changes (Table II I). A similar dose o f  d iazepam induced marked  
lethargy: the animals  could  be placed on their sides and they slept for the fo l lowing 
hour.  E lec t roencepha lography  revealed a h igh-ampl i tude  rhythm with an increase 
in background delta activity. These changes were conf i rmed by the marked  increase 
in power  and percentage delta act iv ity as measured by spectral  analysis. The  
MDF,  the percentage theta activity, and the percentage a lpha act iv ity decreased 
(Table II I). 
Table IIL Changes in the Parameters of Spectral AnalysisforControl Rabbits Afier Treatment with 
Flumazenil or Diazepam a 
Percentage 
Rabbit MDF 
No. (Hz) Power Delta Theta Alpha Beta 
Flumazenil 
1 +0.1 +0.53 -0.3 - 1.8 +0.7 + 1.4 
2 + 0.5 - 43.67 - 3.9 + 0.5 + 0.8 + 2.6 
3 + 0.4 - 20.59 - 5.6 + 2.7 - 1.2 + 3.6 
4 +0.5 - 13.41 -6.0 +2.0 +2.2 + t.8 
Diazepam 
1 - 1.7 +484.62 +25.3 - 17.3 - 5.8 -2.2 
2 - 0.4 + 713.36 + 15.6 - 16.5 - 2.7 + 3.6 
3 -0.5 +612.85 +8.4 -5.7 -4.4 + 1.5 
a Results are expressed as the changes with respect o the baseline values after diazepam or flumazenil minus 
these changes after the placebo; the change in power is expressed as the percentage change assuming that 
the power at baseline was 100%. 
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DISCUSSION 
We could not demonstrate a beneficial effect of flumazenil on hepatic encephalo- 
pathy in our animal model of acute hepatic failure. Our findings are in accordance 
with the results from a rat model of acute ischemic liver failure (Zieve et al., 1987). 
An important role for an endogenous benzodiazepine-like compound in this animal 
model therefore seems unlikely. Our findings are contrary to the results of experimental 
controlled studies on benzodiazepine antagonists in galactosamine- and thioacetamide- 
induced acute liver failure (Baraldi et al., 1984; Bassett et al., 1987; Gammal et al., 
1988; Zeneroli et al., 1988). 
In the galactosamine animal models the effect of a benzodiazepine antagonist 
was investigated only during mild hepatic encephalopathy. All rats apparently 
regained normal clinical status (Baraldi et al., 1984) and neurological response scores 
improved in 75-100% of the rabbits (Bassett et al., 1987). Disturbed visual evoked 
responses normalized in both studies (Baraldi et al., 1984; Bassett et al., 1987). We 
could not demonstrate a clinical effect of flumazenil in any of the rabbits in stage A. 
The upper limit of the 95% confidence interval for this response in eight rabbits, 
36.9%, is therefore still much lower than the responses observed in the galactosamine 
models (Baraldi et al., 1984; Bassett et al., 1987). Furthermore, the MDF after 
flumazenil neither normalized to the baseline value nor showed an improvement 
significantly different from that in the animals receiving the placebo. Regarding the 
95% confidence intervals for the difference in effect on the MDF between flumazenil 
and placebo (-0.54 to 1.16Hz at stage A and -0.68 to 2.82 Hz at stage B), a small 
effect of flumazenil cannot be excluded. Nevertheless, a discrepancy exists between the 
results in the galactosamine animal models (Baraldi et al., 1984; Bassett et al., 1987) 
and the results in our model of acute ischemic liver failure. 
We used a highly reproducible rabbit model in which acute hepatic failure was 
induced by a two-stage liver devascularization procedure. Liver failure was confirmed 
by a decrease in clotting factors and a rise in arterial ammonia levels. All animals 
developed encephalopathy, as confirmed by the occurrence of two easily recognisable 
features of the encephalopathy: a disturbed righting reflex in all and loss of the ability 
to maintain posture. The survival of the animals after induction of liver ischemia was 
similar to that reported after total hepatectomy (Svedberg et al., 1983), which 
confirms the suitability of this animal model. Recently, the usefulness of an ischemic 
animal model for the study of hepatic encephalopathy as been questioned (Jones 
et al., 1987); however, scientific evidence is not available for this statement. 
The concept of investigating the effect of a benzodiazepine antagonist on hepatic 
encephalopathy originated from studies on galactosamine-induced liver failure in 
rats and rabbits, in which increased numbers of brain GABA and benzodiazepine 
receptors were demonstrated using ligand-membrane binding essays (Baraldi et al., 
1982, 1984; Schafer et al., 1983). Both flumazenil and CGS 8216 were found to have 
a beneficial effect in these animal models (Baraldi et al., 1984; Bassett et al., 1987) 
and antagonism ofendogenous benzodiazepine-like compounds was suggested. How- 
ever, later studies on the number of GABA and benzodiazepine receptors in different 
animal models of hepatic encephalopathy, including the rat model of acute ischemic 
liver failure, yielded no changes in GABA and benzodiazepine receptors (Thompson 
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et al., 1985; Maddison et al., 1987a, b; Ferenci et al., 1987; Pappas et al., 1987; Roy 
et al., 1988). Furthermore, the finding of increased numbers of brain GABA and 
benzodiazepine receptors in the galactosamine rabbit model has recently been retracted 
(R6ssle et aI., 1989). Nevertheless, increased GABA-ergic tone is still postulated in 
this animal model (R6ssle et al., 1989). A beneficial effect of a benzodiazepine 
antagonist on hepatic encephalopathy may be found only in an animal model in which 
the influence of the GABA-benzodiazepine r ceptor complex on central nervous 
system function is enhanced. 
Another consideration seems worthwhile. Flumazenil may bind not only to 
central benzodiazepine r ceptors. A beneficial effect of flumazenil upon blood- 
pressure homeostasis was demonstrated in an animal model of hemorrhagic shock 
(Bitterman et al., 1987). A drop in blood pressure has been reported in galactosamine- 
induced liver failure (Gr/in et al., 1976; Brachtel et al., 1988) and may have contri- 
buted to the encephalopathy in this animal model of acute hepatic failure. 
Differences in the types and doses ofbenzodiazepine antagonists might also explain 
the discordance between different studies. In the only published study on rabbits (with 
galactosamine-induced liver failure), a dose of 1-2.5 mg/kg of flumazenil was used to 
ameliorate hepatic encephalopathy (Bassett et al., 1987). We used a higher dose: 
5 mg/kg. This dose has been proven to antagonize marked benzodiazepine-induced 
slowing of the EEG in healthy rabbits, without causing any changes when given alone 
(Gogolfik et al., 1985). To confirm the absence of an intrinsic benzodiazepine-like 
effect of flumazenil when given at this rather high dose, we compared the effects of a 
dose of 5 mg/kg of flumazenil and diazepam in healthy rabbits. Contrary to diazepam, 
flumazenil induced neither behavioral changes nor slowing of the electroencephalo- 
gram. Therefore, our negative findings cannot be explained easily by dose differences. 
We studied the effect of flumazenil n both early and late hepatic encephalopathy. 
Since no effect of flumazenil could be detected in stage A, which occurred early in the 
course of the experiment, when brain edema was almost certainly absent, our negative 
findings cannot easily be explained by the presence of brain edema. 
Flumazenil has been suggested to be of benefit in the treatment of hepatic 
encephalopathy in some uncontrolled clinical studies (Scollo-Lavizzari et al., 1985; 
Bansky et al., 1985, 1989; Ferenci et al., 1989; Burke, 1988; Grimm et al., 1988). 
However, negative results have now also been forthcoming (Sutherland et al., 1988; 
Klotz et aI., 1989; Van der Rijt et al., 1989). Furthermore, GABA and benzodiazepine 
receptors were found to be unchanged inautopsied brain tissue from cirrhotic patients 
with hepatic encephalopathy (Butterworth et al., 1988). At present, no unequivocal 
evidence for an increased GABA-ergic tone is present in human hepatic encephalo- 
pathy. Our negative findings on the effect of flumazenil n our animal model of hepatic 
encephalopathy warrant further caution for its postulated benefit in clinical hepatic 
encephalopathy. 
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